Weekly doses of albumin-bound paclitaxel particles lead to longer survival and are better tolerated than solvent-based paclitaxel in patients with advanced NSCLC, according to the results of a phase 3 study presented at the 2012 American Association of Clinical Oncology Annual Meeting.
Icotinib can provide OS benefits similar to gefitinib in patients with advanced NSCLC, according to final OS and updated biomarker analysis results from the randomized phase 3 ICOGEN trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Oral ridaforolimus is generally well tolerated and significantly improves PFS in metastatic sarcoma patients, according to the results of the phase 3 SUCCEED trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.
High MET expression may predict clinical benefit in patients with locally advanced or metastatic gastric or esophagogastric function cancer treated with rilotumumab plus epirubicin, cisplatin, and capecitabine, according to results of a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Trastuzumab-naïve metastatic breast cancer patients have significantly higher clinical benefit rates and longer OS times when treated with HER2-targeted therapies, compared with patients who previously received adjuvant trastuzumab, according to a study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Chemoradiotherapy with FOLFOX does not improve PFS compared with cisplatin and 5-FU in patients with esophageal cancer and has similar toxicities, according to the final results of a phase 3 study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
There was no significant difference in PFS between BEACOPP and ABVD regimens in patients with stage III-IV high-risk Hodgkin lymphoma, according to a phase 3 clinical trial presented at the 2012 American Association of Clinical Oncology Annual Meeting.
Adding bevacizumab to etoposide and cisplatin (BEEP) has significant anti-tumor effects in breast cancer patients with brain metastases after whole-brain radiotherapy, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Second-line treatment with axitinib showed superior PFS but not OS compared with sorafenib in metastatic renal cell carcinoma previously treated with cytokines, according to updated tiral results reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Single-agent carfilzomib is efficacious in patients with relapsed and double-refractory/intolerant multiple myeloma, according to updatedtrial results presented at the 2012 American Association of Clinical Oncology Annual Meeting.
Please login or register first to view this content.
